Table 6.
Average signal score and average masking effect for Bell's palsy, myocarditis, pericarditis, appendicitis, pulmonary embolism, herpes zoster, and tinnitus
| Adverse event | Pfizer-BioNTech | Moderna | ||||
|---|---|---|---|---|---|---|
| RGPS | MGPS | Masking effect size | RGPS | MGPS | Masking effect size | |
| Bell's palsy | 2.41 | 1.70 | 42% | 1.69 | 1.22 | 39% |
| Myocarditis | 5.40 | 1.66 | 190% | 4.35 | 1.55 | 196% |
| Pericarditis | 2.60 | 1.47 | 72% | 2.02 | 1.17 | 71% |
| Appendicitis | 7.61 | 3.94 | 110% | 5.22 | 3.05 | 107% |
| Pulmonary embolism | 7.18 | 2.88 | 178% | 7.05 | 3.48 | 167% |
| Herpes zoster | 1.23 | 0.44 | 229% | 0.96 | 0.34 | 232% |
| Tinnitus | 3.02 | 1.63 | 82% | 2.31 | 1.27 | 80% |
The average signal score for an AE is based on the individual signal scores underlying its time series displayed in Figs. 1 and 2. Average masking effect size is defined in Sect. 2.5 (not to be confused by the ratio of average signal scores for RGPS and MGPS in the table)
AE adverse event, MGPS Multi-item Gamma Poisson Shrinker, RGPS Regression-Adjusted Gamma Poisson Shrinker